Regarding Cogentin use with Prolixin, which statement is true?

• A. It increases EPS risk
• B. It prevents EPS but may reduce Prolixin efficacy
• C. It has no effect on side effects
• D. It exclusively treats tardive dyskinesia

Answer: (B)

Extrapyramidal symptoms from high-potency typical antipsychotics come from blocking dopamine in the nigrostriatal pathway. Benztropine (Cogentin) is an antimuscarinic that reduces the overactivity of acetylcholine in that same pathway, helping to restore the balance with dopamine and thus prevent or lessen EPS such as dystonia, rigidity, and akathisia. That is why it’s effective to use with Prolixin.

At the same time, anticholinergic meds can produce cognitive and systemic side effects—dry mouth, constipation, urinary retention, blurred vision, confusion—that can complicate overall clinical response. In some patients, this anticholinergic effect can blunt or obscure the antipsychotic’s efficacy in ways that might be interpreted as reduced therapeutic benefit from Prolixin. So the statement that Cogentin prevents EPS but may reduce Prolixin efficacy reflects both the motor benefit and the potential impact on overall treatment response.